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Abstract
Aminoacyl-tRNA synthetases (ARSs) catalyze the first step of protein biosynthesis (canonical
function) and have additional (non-canonical) functions outside of translation. Bi-allelic path-
ogenic variants in genes encoding ARSs are associated with various recessive mitochondrial
and multisystem disorders. We describe here a multisystem clinical phenotype based on bi-
allelic mutations in the two genes (FARSA, FARSB) encoding distinct subunits for tetrameric
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cytosolic phenylalanyl-tRNA synthetase (FARS1). Interstitial lung disease with cholesterol
pneumonitis on histology emerged as an early characteristic feature and significantly deter-
mined disease burden. Additional clinical characteristics of the patients included neurological
findings, liver dysfunction, and connective tissue, muscular and vascular abnormalities.
Structural modeling of newly identified missense mutations in the alpha subunit of FARS1,
FARSA, showed exclusive mapping to the enzyme's conserved catalytic domain. Patient-
derived mutant cells displayed compromised aminoacylation activity in two cases, while
remaining unaffected in another. Collectively, these findings expand current knowledge
about the human ARS disease spectrum and support a loss of canonical and non-canonical
function in FARS1-associated recessive disease.
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1 | INTRODUCTION
Aminoacyl-tRNA synthetases (ARSs) are ubiquitous enzymes that fulfill an
essential role in protein biosynthesis by covalently linking a tRNA molecule
to its cognate amino acid. In addition, ARSs have key functions in various
cellular pathways outside of translation.1-3 In humans, two subsets of ARSs
can be distinguished based on their cytoplasmic or mitochondrial localization.
With rare exception, separate genes, unique for each amino acid, encode for
both cytoplasmic and mitochondrial ARSs. More than 60 disorders are asso-
ciated with mutations in ARS genes and, depending on their individual geno-
type, follow both dominant or recessive inheritance patterns.4-10
Cytosolic phenylalanyl-tRNA synthetase (FARS1) ranks among the
most complex of the ARSs with a hetero-tetrameric structure, consisting
of two FARS alpha (FARSA) and two FARS beta (FARSB) subunits.11 The
hypothesis that both genes may be associated with a similar multisystemic
human disease, including features of interstitial lung disease, liver disease,
neurological manifestations, and growth restriction (MIM: 619013,
613 658), needs further support. Whereas 11 individuals presenting with
bi-allelic mutations in FARSB are described,9,12,13 information on FARSA-
related disease is rare and comes from a single case report describing a
patient with mutations in FARSA and features of interstitial lung disease,
cerebral and skeletal abnormalities, hypotonia, and liver dysfunction.10
Here, we report three unrelated individuals with identified bi-allelic vari-
ants in FARSA (MIM: 602918), and two unrelated individuals presenting bi-
allelic variants in the gene encoding the beta subunit, FARSB (MIM: 609690).
We provide biochemical and functional proof of novel genetic variants, spot-
light the value of rare but indicative interstitial lung disease as a clue for diag-
nosis, give details on the long-term clinical course including treatment and
outcome, and review the spectrum of FARS1-associated recessive disease.
2 | MATERIAL AND METHODS
Patients were recruited from the European Management Plat-
form for Interstitial Lung Disease (chILD-EU) registry by
searching the database for children with chronic interstitial lung
disease of unknown cause, and in-depth analysis of ARS genes
by whole exome sequencing (WES) was performed. Six subjects
with predicted disease-causing variants in FARSA and FARSB
were retrieved, one was published independently.10 Patients
and families gave their written informed consent to participate
in the chILD-EU consultation and diagnosis program. All human
subject research was in accordance with current ethical stan-
dards and approved by the Ethics Committee of the University
of Munich, Germany (EK 111–13, EK 20–329).
2.1 | Whole exome sequencing and variant
prioritization
Genomic DNA was isolated from whole blood using the QIAmp
DNA Mini Kit (Qiagen, Hilden, Germany) according to the manu-
facturer's instructions. Exonic regions were enriched with Sur-
eSelectXT Human All Exon V6 + UTR kit (Agilent, Santa Clara,
CA) and sequenced as 150 bp paired-end runs on an Illumina
NextSeq500 (ILLUMINA, San Diego, CA). Reads were aligned to
the human reference genome GRCh37 by Burrows-Wheeler
Aligner (v.0.7.15).14 Genome Analysis Tool Kit (GATK v3.8)15
software was used to analyze the data. Functional annotation
was added using Variant Effect Predictor (VEP), Ensembl release
95.16 Rare variants (MAF < 1%) were filtered using an in-house
SQL database incorporating frequency information from the
1000 Genomes Project17 and gnomAD.18 Filtered variants were
evaluated based on predicted pathogenicity scores and an auto-
somal recessive inheritance pattern including homozygous and
compound heterozygous variant pairs identified by Smart-
Phase.19 All patients were analyzed as trios; variants that
remained after filtering are presented in Table S2. Sanger
sequencing was used to confirm the identified mutations in
FARSA and FARSB and to determine the carrier status of parents
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and the unaffected sibling in family 1 (for primers, see supple-
mentary information S1).
2.2 | Histopathology, isolation of patient-derived
cell lines and cell culture
Tissue for diagnosis was obtained by open lung biopsy. Following for-
malin fixation and paraffin embedding, slides were stained with
Hematoxylin–Eosin (HE), Elastica van Gieson (EvG), Prussian Blue, and
Periodic Acid-Schiff (PAS). All readings were made by a pathologist
specialized in pediatric interstitial lung disease.
Fibroblasts were obtained from skin punch biopsy of affected
individuals and cultured in Dulbecco's Modified Eagle Medium/F12
(DMEM) (Pan Biotech, Aidenbach, Germany) supplemented with 10%
FBS (Sigma-Aldrich, St. Louis, MO) (vol/vol), and 1% Antibiotic-
Antimycotic (Thermo Fisher, Waltham, MA) (vol/vol) at 37C and 5%
CO2. Cells were regularly split after reaching confluency of 80%–90%.
PBMCs were isolated from whole blood samples by density gradi-
ent centrifugation with Biocoll (Merck, Darmstadt, Germany) and sub-
sequently incubated with B95-8 cell supernatants (Leibniz Institute,
DSMZ, Germany) and 0.01% cyclosporine A (Sigma-Aldrich) (wt/vol)
to give rise to Epstein–Barr Virus Immortalized Lymphoblastoid Cell
Lines (EBV-LCLs). Cells were maintained in RPMI 1640 medium with
GlutaMAX™ (Thermo Fisher), supplemented with 10% FBS (Sigma-
Aldrich) (vol/vol), 10 mM HEPES (Thermo Fisher), and 1% Antibiotic-
Antimycotic (Thermo Fisher) (vol/vol) at 37C and 5% CO2.
2.3 | Modeling of the human FARS1-tRNAPhe
complex structure
The structure of the Thermus thermophilus tRNAPhe molecule (PDB:
2IY5)20 was aligned with the crystal structure of human FARS1 (PDB:
3L4G)21 using PyMOL22 to model the position of tRNAPhe and the
phenylalanyl-adenylate.
2.4 | Conservation analysis of FARSA amino acid
residues
Conservation analysis was performed with ConSurf Server.23 Initial
sequence selection was performed on the Uniref90 database using an E-
value threshold of 0.0001. Within this pool, the best 70 FARSA sequences
were manually selected. Final alignment was performed with the MAFFT-
L-INS-i method and scoring was calculated using the Bayesian method.
2.5 | RNA isolation and quantitative reverse
transcription PCR
Total RNA was isolated from cultured cells using the High Pure RNA Isola-
tion Kit (Roche, Basel, Switzerland). RNA yield and purity were measured on
a NanoDrop spectrophotometer (NanoDrop Technologies, Thermo Fisher).
1 μg of RNA was subsequently reverse transcribed with the Tetro cDNA
Synthesis Kit (Bioline, Meridian Bioscience, Cincinnati, OH). Real-Time PCR
was performed in a thermal cycler (StepOnePlus, Applied Biosystems,
Thermo Fisher) with SensiFast SYBR Hi-ROX reagent (Bioline) capturing tar-
get genes FARSA, FARSB, and the ribosomal internal control gene RPS29
(primers, see supplementary information S1). Fold change of target gene
expression was calculated based on the comparative CT method.
24
2.6 | Western blot and densitometry
Cells were lysed in radioimmunoprecipitation assay buffer (0.15 M
sodium chloride, 1% Triton X100 [vol/vol], 0.5% sodium deoxycholate
[Sigma-Aldrich] [wt/vol], 5 mM ethylenediaminetetraacetic acid
[GE Healthcare, Chicago, IL], 50 mM Tris [pH = 8] [Merck]). 20 μg of
protein were subjected to polyacrylamide- gel electrophoresis on a
NuPage Mini 3%–8% Tris-Acetate gel (Thermo Fisher) and blotted to
a polyvinylidene fluoride membrane (Merck). Antigen targets were
detected using the rabbit polyclonal primary antibodies anti-FARSA
18121-1-AP (Proteintech, St. Leon-Rot, Germany), and anti-FARSB
HPA036677 (Sigma-Aldrich), followed by incubation with HRP-
conjugated goat anti- rabbit IgG (H + L) secondary antibody (Thermo
Fisher). Β–actin quantification (sc-47 778 HRP, Santa Cruz, Dallas, TX)
served as a loading control. Proteins were detected using SuperSignal
West Femto Maximum Sensitivity Substrate (Thermo Fisher). Relative
band intensities were analyzed using the Image J software.25
2.7 | Aminoacylation assay
FARS1 activity was assessed by steady-state aminoacylation assays in cells
of patients and family members. Cytosolic fractions of lysates were incu-
bated at 37C with 0.3 mM [D5]-phenylalanine and [D2]-tyrosine
(Cambridge Isotope Laboratories, Tewksbury, MA) in a 50 mM Tris buffer,
pH 7.5, containing 1 mM ATP, 0.2 mM yeast total tRNA, 1 mg/ml bovine
albumin serum, 12 mM MgCl, 25 mM KCl and 1 mM dithiothreitol (all
Sigma-Aldrich). [13C]-phenylalanine and [13C9]-tyrosine (Cambridge Isotope
Laboratories) were added as internal standards. Labeled amino acids were
quantified by liquid chromatography–tandem mass spectrometry. Intra-
assay variation was <15%. For kinetic studies, Km and Vmax values for phe-
nylalanine and tyrosine were calculated by measuring six different concen-
trations in the range of 0.009–0.6 mmol/L. Data were subsequently
analyzed using Graph Pad Prism 8.2.1 (GraphPad Software, La Jolla, CA).
3 | RESULTS
3.1 | Clinical characteristics of patients with newly
identified FARSA/FARSB variants
All five unrelated patients (P1, P2, P3, P16, P17) with novel bi-allelic
variants in FARSA or FARSB (Figure 1) were identified clinically due to
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their prominent and distinct pulmonary phenotype. Common to all
was a peculiar chronic interstitial lung disease starting early in life and
characterized by bilateral ground-glass opacification on HR-CT, and
cholesterol pneumonitis in lung histology. Additional abnormalities in
other organ systems were summarized, suggesting a multi-organ dis-
order (Figure 4, Table S1).
Patient 1 was born hypotonic with hyperflexible joints, had arach-
noid fingers and delayed motor development. At the age of 5 years,
F IGURE 1 Family pedigrees with segregation of newly identified variants in FARSA (NM_004461.3, NP_004452.1) (A) or FARSB
(NM_005687.5, NP_005678.3) (B) confirmed by Sanger sequencing. Predicted effects on cDNA and protein for affected and unaffected
individuals are indicated. Patients are marked P1-P3 (FARSA) and P16, P17 (FARSB). For families 2, 3, and 17, consanguinity of the unaffected
parents was reported [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE 2 Histopathology of the lungs. (A) Prominent cholesterol pneumonia with intra-alveolar and interstitial cholesterol granulomas. Note
combination with fresh and older bleeding with accumulation of iron-storing macrophages, and megakaryocyte emboli resulting from pulmonary
hypertension (insert arrow) (P1, age of 8.6 years; hematoxylin–eosin (HE) staining; in upper left panel, scale bar 500 μm; insert, scale bar 50 μm,
and upper right panel, scale bar 100 μm; iron (Prussian Blue, FE) staining in lower left panel and lower right panel, scale bar 500 and 200 μm).
(B) Pulmonary alveolar proteinosis with dense intra-alveolar accumulation of Periodic acid–Schiff (PAS)-positive granules and cholesterol clefts
(P2, age of 8 months; HE-staining in upper panels, scale bar 200 μm (left) and 100 μm (right), PAS-staining in lower panels, scale bars 100 μm)
[Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE 3 Legend on next page.
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growth hormone resistance (Laron-type, no molecular confirmation)
was diagnosed, and IGF-1 treatment was applied for 6 years (reaching
20th percentile for height). Her brain MRIs at the age of 8.8 and
9.5 years demonstrated multiple unspecific white matter lesions in a
predominantly subcortical location, increased in number and size at
the age of 17 years. Elongated brain arteries were noted (Figure 3(A–
D)). She had hepatosplenomegaly and abdominal ultrasound revealed
steatosis of the liver. At the age of 8.4 years, she presented with a
protracted respiratory tract infection, was severely hypoxemic on
admission, and needed intubation and ventilation for 2 weeks.
Bilateral clubbing was noted. Cardiac echo (at age 8.7 years) gave
slightly elevated pulmonary artery pressures, and 7 years later, there
was no evidence for pulmonary hypertension. After recovery, she had
a forced vital capacity of 73% of predicted, oxygen saturation during
sleep between 88% and 91%, and normal pCO2. Her chest X-ray
showed bilateral ground-glass and reticular opacities. Chest CT ini-
tially showed patchy consolidations which resolved over time,
whereas fibrosing lung disease became more prominent (Figure 3(J)).
Lung biopsy demonstrated intra-alveolar and interstitial cholesterol
granulomas, in combination with pulmonary hemorrhage at the age of
8.6 years, consistent with cholesterol pneumonia (Figure 2(A)). The
course of lung disease was progressive (Figure 3(I)) despite various
treatments, including a protein-rich diet and phenylalanine substitu-
tion. Currently she is stable at low lung function and evaluated for
lung transplantation.
Patient 2 was referred at 1 month of age for failure to thrive,
vomiting, chronic loose stools without pancreatic insufficiency, hyper-
phosphaturia, and osteopenia. An initial examination revealed
hepatosplenomegaly, also on CT (Figure 3(F)), with hypoalbuminemia,
increased neutral lipid storage in hepatocytes, and signs of focal fibro-
sis and cholestasis in liver biopsy. On physical examination, she had
visible and palpable subcutaneous fat pads on her forearms and
around her knees. She had hypotonic muscle tone, intermittent nys-
tagmus, and a global neurodevelopmental delay. Brain ultrasound was
normal. The infant was tachypneic since 5 months of age and suffered
from recurrent respiratory infections up to the age of 1 year. Initial
and consecutive chest X-rays showed bilateral homogenous ground-
glass opacities, bronchial wall thickening and generalized overinflation,
and chest CTs revealed interlobular septal thickening and crazy-paving
pattern, increasing over time, despite therapeutic lung lavage
(Figure 3(L)). Lung biopsy confirmed pulmonary alveolar proteinosis
with intra-alveolar and intraseptal cholesterol crystals (Figure 2(B)).
Over time respiratory distress increased. A therapeutic lavage
removed 62 g of protein from the right lung, however, the infant died
of respiratory failure at the age of 1.3 years.
Patient 3 was referred at the age of 5 years for recurrent lower
airway infections and chronic cough for more than 3 months. He had
growth retardation, pectus carinatum, digital clubbing, and a sensori-
neural hearing defect (Figure 3(G,H)). A CT scan at the age of
7.5 years demonstrated ground-glass opacification and reticulation,
bilateral emphysema, bullae, nodules, focal consolidations, emphy-
sema, and air trapping on expiration (Figure 3(N)). Lung biopsy showed
hyperinflated and emphysematous airspaces with an increased infiltra-
tion of inflammatory cells and cholesterol pneumonia. In addition,
growth hormone deficiency was detected, and cranial MRI revealed
an arachnoid cyst (Figure 3(E)), but he presented neurologically nor-
mal. Despite various treatments, his clinical status deteriorated gradu-
ally with increasing hypoxemia, dyspnea, pronounced pectus
carinatum, slightly altered liver enzyme values, and failure to thrive.
After a several months period of increasing respiratory distress, he
died of respiratory failure at the age of 12.9 years.
Patient 16 suffered from a mild bronchiolitis at the age of
2 months and a self-limiting bronchitis at the age of 7 months. At the
age of 2 years, digital clubbing was observed on an emergency visit
for gastroenteritis. He was asymptomatic with normal oxygen satura-
tion on room air, however, chest X-ray and CT scan revealed diffuse
ground-glass opacities, septal thickening, and subpleural cysts
(Figure 3(M)). Lung tissue showed cholesterol granulomas and clefts,
pneumocyte hyperplasia, and mild fibrous septal thickening. Due to
chronic moderate headaches, brain MRI was performed at the age of
8 years and revealed bilateral focal and non-confluent gliotic-
demyelinating lesions with dilated perivascular spaces. At the age of
10 years, he was diagnosed with sensorineural hearing loss. Other-
wise, neurological examination was unremarkable. An abdominal ultra-
sound revealed mildly diffuse hyperechoic liver parenchyma and renal
asymmetry with a smaller right kidney. Currently at the age of
F IGURE 3 (A,B) Cranial MRI, axial T2-w images (P1, age 17 years) with multiple non-specific white matter lesions in a predominantly
subcortical location, which may indicate cerebral small vessel disease. MR-Angio (C) and T2-w sagittal image (D) show an unusual elongation of
both vertebral arteries and the basal artery as well as of all arteries of the circle of Willis (arrows). No aneurysms present. (E) T2-w cranial MRI
with large arachnoid cyst (P3, age 5 years). (F) Liver enlargement in CT with hypodense liver parenchyma likely representing fatty liver (P2, age
10 months). (G,H) Images of P3 highlighting pectus carinatum, failure to thrive, and digital clubbing (age 12 years). (I) Restrictive lung disease in
early childhood with rapid progression. FEV1, forced expiratory volume in 1 s, FVC, forced vital capacity. (J) Chest CT (P1, 8.4 years) (first left)
with bilateral diffuse ground-glass attenuation, interstitial reticular markings, and patchy consolidations. Overtime (ages 8.8, 11, 17 years) (from
left to right) development of many small periseptal and subpleural cysts, diffuse ground-glass opacities, and pronounced pectus carinatum, loss of
volume, architectural distortion. (K) Therapeutic bronchoalveolar lavage of the right lung (P7, age 5 years). Protein wash-out with six lavage
cycles. (L) Axial HR-CT (only right side shown) before (upper panel) and 1 day after (lower panel) therapeutic lavage of the middle lobe with
almost complete clearance of the diffuse ground-glass opacification and interlobular septal thickening in concert with increasing pleural effusion
and dependent consolidation in the lower lobe (P2, age 10 months). (M) Chest CT with diffuse ground-glass opacities and numerous subpleural
cysts (P16, age 8 years). (N) Chest CT with characteristic pectus carinatum chest deformity and differently shaped subpleural bullae and
emphysematous changes, pleural thickening, multiple intraparenchymal lung cysts, and bilateral hilar lymphadenopathies (P3, age 7.5 years)
[Colour figure can be viewed at wileyonlinelibrary.com]
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13 years, he presents with persistent failure to thrive. He follows a
protein-rich diet that he was recommended to adhere to. On physical
examination, lung auscultation and resting oxygen saturation are nor-
mal, but he still shows prominent digital clubbing. Lung function tests
show a reduced spirometry and diffusing capacity for CO (58% of
predicted) (Figure 3(I)).
Patient 17 was referred at the age of 8 years for failure to thrive
and chronic cough and dyspnea, persistent for 1 year. On physical
examination, she presented with pectus excavatum and digital club-
bing. Chest X-ray showed bilateral interstitial appearance and CT scan
identified diffuse ground-glass opacities and cysts, subpleurally and
scattered throughout all lobes. Lung biopsy revealed cholesterol pneu-
monia associated with mild chronic interstitial inflammation and fibro-
sis, foam cell aggregates, mild lymphoid hyperplasia without lymphoid
follicles, and mild chronic pleuritis with fat metaplasia. She has a his-
tory of chronic diarrhea from the age of 3 months, which improved
over time with a specific formula of nutrition. Due to proteinuria and
hypoalbuminemia, further nephrological and metabolic diagnostics
were performed; however, no other abnormalities were detected. An
abdominal ultrasound was normal. Currently at the age of 12 years,
she has reduced resting oxygen saturation around 90% and is on long-
term oxygen supplementation.
3.2 | Bi-allelic variants in FARSA and FARSB cause
FARS1-related disorders
Review of the clinical features of the five unrelated patients with novel
bi-allelic variants in FARSA or FARSB and previously published cases
described a complex phenotype, manifesting during early childhood, after
an uneventful neonatal period (Figure 4). Besides the common distinct
pulmonary phenotype and failure to thrive, abnormal neuromuscular fea-
tures occurred in more than two thirds of the patients. About half of the
subjects had abdominal and hepatic abnormalities. Less frequent findings
in multiple other organ systems were present at similar prevalence, inde-
pendent of the underlying FARS1 subunit affected.
Exome sequencing identified compound heterozygous FARSA vari-
ants c.(1210C > T), p.(R404C) and c.(1254G > C), p.(E418D) (de novo) in
patient 1 and homozygous variants (c.883 C > T), p.(R295W) and c.
(829 T > G), p.(F277V) in patient 2 and 3, both with consanguineous
family background. Compound heterozygous FARSB variants c.
(1084 T > C), p.(C362R) and c.(1201C > T), p.(R401*) were identified in
patient 16 and homozygous variants c.(229C > T), p.(L77=) and c.
(1685G > T), p.(G562V) in patient 17 with consanguineous family back-
ground. Variants were annotated on NM_004461.3 (NP_004452.1) and
NM_005687.5 (NP_005678.3), respectively (Figure 1).
3.3 | FARSA variant effect prediction on protein
structure
With the exception of patient 2 (R295W, average conservation), the
presented variants in FARSA were strictly conserved (Figure S1) and
absent or extremely rare in gnomAD (Table S1A). Structurally, the
FARSA protein consists of two main regions. The N-terminal site con-
tains three subdomains with characteristic helix-turn-helix structures,
forming a DNA/dsRNA binding domain (DBD1/2/3) and likely func-
tioning to recognize and bind tRNAPhe. The DBD-domain connects
through a linker region to the C-terminal catalytic domain with
subdomains A1/A2 which participate in tRNA binding and
aminoacylation.21,26 All identified variants were located exclusively in
the A1/A2 domain (Figure 5(A)).
To investigate the impact of both these and previously reported
variants10 on FARS1 structure and function, we aligned
T. thermophilus tRNAPhe (PDB: 2IY5) with the crystal structure of
human FARS1 (PDB: 3L4G) (Figure 5(B)). In this model, three residues
affected by the missense mutations potentially interfere directly with
the catalytic activity, due to their proximity to the active site: E418D,
N410K, and F256L. The first, E418, interacts with conserved residues
K406, E431, and N434 and is located close to the 30 end of the tRNA,
where phenylalanine is loaded. The substitution by aspartate incorpo-
rates a shorter side chain that might interfere with this hydrogen net-
work and either affects tRNA binding or the transfer of the amino
acid from its binding site to the tRNA (Figure 5(Ci)). The second,
N410, forms two hydrogen bonds with the conserved residue N434.
These bonds have previously been predicted to influence rigidity of
the phenylalanine binding site21 and the substitution by lysine at this
position will very likely modify the conformation of the active site
(Figure 5(Cii)). The third, F256, is an absolutely conserved residue in a
very well conserved region (amino acids 253–278). Structurally, it is
located at the back of the active site in a hydrophobic pocket com-
posed of aromatic and hydrophobic residues (W257, P289, Y292,
V293, A261, A319). The substitution by leucine conserves the hydro-
phobic nature of the residue, albeit to a lesser extent, and might
slightly destabilize the pocket, thus affecting the active site
(Figure 5(Ciii)).
The other variants F277V, R404C, and R295W primarily affect
residues close to interfaces between subunits A/B and might interfere
with the overall structure of the FARS1 complex. Residue F277 is
located at a strong hydrophobic pocket at the interface between sub-
units and is composed of strictly conserved residues on both subunit
sides. Based on the aligned homologous structures, it is also in close
proximity with the tRNA. Given the strict conservation of the inter-
face, it is likely that functional FARSA/B is destabilized by the substi-
tution, thus likely affecting its enzymatic activity (Figure 5(Civ)). R404
is a well conserved residue (98%) close to the active site, but it is also
located near an interface with FARSB and likely forms hydrogen
bonds with E26 from FARSB and the strictly conserved W429 from
FARSA. A substitution by cysteine (R404C) would impact this hydro-
gen bond network and might impact the interactions between sub-
units. Alternatively, the substitution might induce conformational
changes down into the proximal active site (12.3 Å), thus directly
affecting the activity (Figure 5(Cv)). The last residue, R295, is solvent
exposed and located in a variable region of the protein. R295 is par-
tially conserved (87% in our alignment) but can be substituted by
other residues containing NH2 groups: lysine (11%) and asparagine
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F IGURE 4 Summarized graphical clinical phenotype of patients with mutations in FARSA or FARSB described here (P1-P3, P16, P17) (marked
in red) or in the literature (P4-P15) (marked in black, see Table S1 for details) (adapted from Ref. 4). Black and white squares reflect positivity and
negativity for symptoms, gray squares reflect presence of symptoms “in most”12 (calculation with 2/3 of individuals). Unknown status is indicated
by the slash symbol [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE 5 Legend on next page.
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(2%) (Figure S2). The side chains likely form two hydrogen bonds with
the backbone carbonyl of the residues P445 and M446. With the sub-
stitution lysine or asparagine, one of these hydrogen bonds could be
conserved. However, the substitution by a tryptophan does not allow
these hydrogen bonds and would potentially weaken the structural
integrity of the region (Figure 5(Cvi)).
3.4 | Aminoacylation activity of FARS1 complex
To further characterize the impact of the mutations on
aminoacylation, FARS1 enzyme activity levels were determined in
fibroblasts or EBV-transformed lymphoblastoid cell lines (EBV-LCLs)
of patients and family members (Figure 5(E)). Patient 1 (E418D/
R404C) had FARS1 activity reduced to 5% in fibroblasts and 50%
in the EBV-LCL. Enzymatic activity in carriers (R404C/WT), that is,
the mother or the brother of patient 1, was normal indicating that
E418D, consistent with its location near the tRNA end, mainly
affects aminoacylation. In contrast, fibroblasts of patient 2 (R295W/
R295W) had normal FARS1 activity level (see also Figure S2). In the
EBV-LCLs of family 3 (F277V/F277V), we found FARS1 activity
decreased to 5% in the patient and 30%–75% in heterozygous
parents, suggesting that F277V reduces aminoacylation activity in a
dose-dependent manner, but does not completely abolish it, reflec-
tive of its hypomorphic nature. All patients and carriers showed nor-
mal FARSA and FARSB transcript and protein expression (Figure 5(D),
Figure S3(A,B,C)).
4 | DISCUSSION
The data provided here support the view that FARS1-associated recessive
disease represents an ample clinical phenotype involving multiple organ
systems caused by a disturbance of cytosolic phenylalanyl-tRNA synthe-
tase. Due to the heterotetrameric structure of the FARS1 complex, con-
sisting of two alpha and two beta subunits, we expect a common
underlying pathomechanism that may be rooted in either bi-allelic variants
in FARSA, the gene encoding the alpha subunit of FARS1 or its beta sub-
unit, FARSB.
The FARS1 phenotype manifests in more than 10 organs
(Figure 4) and varies in expression and severity of symptoms inter-
individually. It partially overlaps with the phenotype observed in
other cytoplasmic ARS diseases which commonly present as a broad
multisystem spectrum, typically with a neurological component.5 A
dominant and unifying feature of FARS1 cases was its uncommon
but distinctive interstitial lung disease phenotype, defined by a char-
acteristic chest CT pattern and cholesterol pneumonitis in all individ-
uals where histology was available. The rare pulmonary phenotype
should therefore be an important red flag to start systematic search
for other clinical organ involvement.
The identified variants in FARSA and FARSB were rare
(MAF < 1%), predicted as pathogenic, and detected in trans if com-
pound heterozygous. The majority affect highly evolutionary con-
served amino acid residues (shown for FARSA in Figure S1). Patient
16 presented a missense mutation in combination with a predicted
loss of function allele. This pattern matches the typical recessive ARS
disease genotype, which usually encompasses either homozygosity
for missense mutations, compound heterozygosity for missense muta-
tions or compound heterozygosity for one missense mutation and one
null allele.5
Considering the vital role of ARS genes for protein synthesis,
mutations typically present as hypomorphic rather than loss of
function alleles. Accordingly, we have detected basic FARS1 activ-
ity in all our patient-derived cell lines with cells growing normally.
FARS1 aminoacylation rate was compromised in two patient cell
lines, whereas it was normal in another. Normal ARS activity
in vitro might not necessarily reflect its activity in vivo. Alterna-
tively, the results suggest that aminoacylation may represent a
FARS1 function not pivotal for disease pathogenesis. This concept
is in line with previous mechanistic studies in FARSB mutant
patient-derived cells.9 Bi-allelic FARS1 mutations likely express
their pathogenicity through a yet undetermined molecular pathway
where gene dose has fallen below a critical threshold. Concor-
dantly, several publications link ARSs to a number of essential non-
canonical functions including regulation of metabolic homeostasis,
cell proliferation and differentiation, angiogenesis, tumorigenesis,
and immune response.1,2
Currently, treatment options for FARS1 patients are limited to symp-
tomatic treatment. In some patients (P2, P7; Figure 4) pulmonary alveolar
proteinosis, that is, excessive accumulation of lipoproteins in the alveolar
space, characterizes their interstitial lung disease in addition to cholesterol
pneumonitis. Whole lung lavage treatment achieved transient relief of
respiratory insufficiency in those two subjects treated with this option
(Figure 3(K)). Increasing the substrate, that is, the metabolic concentration
F IGURE 5 FARS1 structure, localization of mutations, protein expression level, and enzymatic activity. (A) Schematic of FARSA protein with
location of missense mutations in the catalytic domain A1/2 (*case report10) (B) Location of mutations in the structural model of FARS1
complexed with tRNAPhe in cartoon backbone representation. Two FARSA chains are colored in light gray and green, two FARSB chains in dark
gray and blue, tRNAPhe in orange. Mutated amino acid residues are shown in black. (C) Predicted impact of mutations on local amino acid
interactions with pairwise comparison between side chains of wildtype residues (left) and modeled missense mutations (right). Mutated residues
are shown in black, the phenylalanyl-adenylate in yellow. Colors blue, red, and yellow highlight single nitrogen, oxygen, and sulfur atoms.
(D) Representative Western blots of FARSA and FARSB protein expression in cells of patients and relatives. (E) FARS1 aminoacylation activity in
cytosolic cell fractions of patients and relatives. Data represent mean ± SD of at least three technical replicates. P3 fibroblasts were unavailable.
DBD, DNA/dsRNA-binding domain [Colour figure can be viewed at wileyonlinelibrary.com]
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of the synthetase's respective amino acid, here phenylalanine, appears to
be a safe therapeutic option which can be instituted in individual patients,
but needs to be addressed in clinical trials. Anecdotal evidence supports
this approach for patients with interstitial lung–liver disease due to muta-
tions in MARS1.27
Novel therapeutic options are expected with a deeper under-
standing of FARS1-linked recessive disease. Its association with a
broad and variable spectrum of symptoms calls for alertness in clinical
practice. Genetic screening for mutations in FARSA and FARSBmay help
guide diagnostics and should be considered for unclear cases of multi-
system disorders in combination with chronic interstitial lung disease.
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